Comparative analysis of KRAS and EGFR mutation detection in liquid biopsy vs tissue biopsy in patients with NSCLC

Comparative analysis of KRAS and EGFR mutation detection in liquid biopsy vs tissue biopsy in patients with NSCLC - COMMUNIST

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48625

Enrollment

150

Registered

2019-03-18

Start date

2019-06-21

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer Non-small-cell lung carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with NSCLC (initial diagnosis and progressive disease) that are eligible for KRAS/EGFR mutation analysis on tissue biopsy as performed for standard of care.

Exclusion criteria

Exclusion criteria: Patients with NSCLC where tissue biopsy was not successful.

Design outcomes

Primary

Measure	Time frame
The agreement between liquid biopsy and tissue biopsy based KRAS/EGFR molecular diagnostics that will be determined using Contigency table analysis and comparison of parameters such as specificity, sensitivity, positive and negative predictive values and Cohen*s kappa coefficient.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results